Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565596 | 0.93 | CYP2C9 (0.45) | CYP2C9CYP2C19HSD17B10TSHRSLC6A2 | |
| SCHEMBL11565004 | 0.93 | HSD17B10 (0.45) | CYP2C9CYP2C19HSD17B10TSHRSLC6A2 | |
| SCHEMBL28695278 | 0.92 | LMNA (0.53) | CYP2C9CYP2C19HSD17B10L3MBTL1TRPA1 | |
| SCHEMBL28695277 | 0.92 | LMNA (0.53) | CYP2C9CYP2C19HSD17B10L3MBTL1TRPA1 | |
| SCHEMBL11565126 | 0.88 | UTS2R (0.45) | CYP2C9CYP2C19HSD17B10L3MBTL1LMNA | |
| SCHEMBL11562550 | 0.86 | LMNA (0.47) | CYP2C9CYP2C19HSD17B10L3MBTL1LMNA | |
| SCHEMBL28600328 | 0.84 | CYP2C9 (0.61) | CYP2C9CYP2C19HSD17B10TSHRSLC6A2 | |
| SCHEMBL9837170 | 0.80 | TRPA1 (0.47) | SLC6A2SLC6A4SLC6A3L3MBTL1TRPA1 | |
| SCHEMBL28465400 | 0.80 | TRPA1 (0.47) | CYP2C9CYP2C19HSD17B10TSHRL3MBTL1 | |
| SCHEMBL20540763 | 0.79 | LMNA (0.65) | TSHRL3MBTL1LMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1663113-A4 | SUBSTITUTED SULFONAMIDES | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1494997-A1 | SUBSTITUTED ARYL AMIDES | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | CYP2C9 1269/4885CYP2C19 732/4885HSD17B10 4401/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | CYP2C9 1884/4885CYP2C19 1058/4885HSD17B10 4497/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | CYP2C9 1269/4885CYP2C19 732/4885HSD17B10 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.